



To: The Copenhagen Stock Exchange
Translation

Announcement no. 2 in 2006/07
September 25, 2006

GRAZAX[®] approved in Europe

Summary: Authorities in 27 European countries have now approved GRAZAX[®], ALK-Abelló's tablet-based vaccine against grass pollen allergy. ALK-Abelló still expects to launch GRAZAX[®] on the first European markets by the end of 2006 and ahead of the 2007 pollen season.

ALK-Abelló today completed the European Mutual Recognition Procedure for GRAZAX[®], the company's tablet-based vaccine against grass pollen allergy, and the authorities in 27 European countries have now approved the tablet vaccine.

ALK-Abelló still expects to launch GRAZAX[®] on the first European markets by the end of 2006 and ahead of the 2007 pollen season. The launch may commence immediately upon receipt of local marketing authorizations and finalized price and reimbursement negotiations with the respective authorities. Timewise, this process varies from country to country.

The Swedish authorities approved GRAZAX[®] in March 2006. The approval now also covers Austria, Belgium, Cyprus, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, the Czech Republic, the Netherlands and the United Kingdom.

Hørsholm, September 25, 2006
ALK-Abelló A/S

Jens Bager
President and CEO

Contact:
Jens Bager, President and CEO, tel. +45 4574 7445

About GRAZAX[®]

GRAZAX[®] is the first allergy tablet that improves the patient's quality of life by treating the underlying cause of the grass pollen allergy and not just the symptoms. GRAZAX[®] is a new and convenient treatment, a fast-dissolving once-a-day sublingual tablet for home administration.